Ryan Potts
@pottslab
VP & Head of Induced Proximity Platform, @Amgen | Scientist | Father
New print posted from the group @Amgen. We describe VIPER-TACs that leverage viral E3 ligases for disease-specific targeted protein degradation. This concept dramatically expands he druggable space to include pan-essential proteins. 🧵 #mycompany biorxiv.org/content/10.110…
DEL is accelerating our Induced Proximity Platform—helping us discover small molecules that rewire cellular processes and bind challenging targets. A powerful example of DNA driving therapeutic innovation. #DNADay #MyCompany
Our DNA-Encoded Library (DEL) platform 🧬 is accelerating drug discovery by rapidly identifying molecules that have the potential to become therapies. This #DNADay, discover how we’re using DNA to advance therapeutics for those in need 🔗: amgen.ly/3EpGvON
Amazing opportunity for recent STEM grads! A paid 2-year fellowship at Amgen with real research, publication potential, and impact on patients
What a mind-blowing week for AI in biology! 🚀 Xaira just dropped the largest genome-wide perturbation dataset ever last week 🧬 Arc unveiled STATE yesterday, the most powerful foundation model for single-cell perturbation prediction 🧠 DeepMind followed up with AlphaGenome,…
🎓 Recent STEM grad? Jump-start your PhD journey with Amgen’s new 2-yr paid Postbaccalaureate Research Fellowship in Thousand Oaks! Work with world-class scientists, publish your findings, and make a real impact for patients. Apply by July 15 ➡️ amgen.wd1.myworkdayjobs.com/Careers/job/US…
Happy to present our latest paper with @pottslab & @Amgen in @J_A_C_S by co-first authors @C_M_Zammit & Cory Nadel on the discovery of a direct-acting covalent destabilizing degrader of AR and the undruggable truncation variant of AR, AR-V7, in androgen-independent prostate…
Excited to announce a new collaboration between the Molecular Therapeutics Initiative (MTI) and Amgen Inc.! This partnership includes funding for cutting-edge research & an internship program for grad students to train in drug discovery & development at Amgen. #MTI #Amgen…
Very cool!
Molecular surface mimicry enables CRBN to target G3BP2 for degradation biorxiv.org/content/10.110… #biorxiv_molbio
Proteome-Wide Discovery of Degradable Proteins Using Bifunctional Molecules biorxiv.org/content/10.110… #biorxiv_biochem
Bacterial ubiquitin ligase engineered for small molecule and protein target identification biorxiv.org/content/10.110… #biorxiv_molbio
.@pottslab @Amgen demonstrate proof-of-concept of disease-specific targeted degradation by redirecting virally encoded E3 ubiquitin ligases with VIPER-TACs. dlvr.it/TJgF11
Congrats to the teams @Amgen & @PlexiumTx for an impressive piece of work. After work by Novartis now providing additional proof that VHL is glueable. The way the team followed through with this study is scientifically amazing. #TPD #proximity
Rational discovery of VHL molecular glues. New Preprint from @Amgen Induced Proximity group led by postdoc Jonathan Bushman reports the discovery of a VHL molecular glue degrader of GEMIN3 by Picowell RNA-seq. Read on for details. 🧵1/7 biorxiv.org/content/10.110…
I thought this paper from @pottslab group at Amgen was fascinating. biorxiv.org/content/10.110… It has everything: Chemical induced proximity focused DELs on beads, small decorations on solvent exposed portions of known binder, one bead per well, photocleavable linkers to…